Alnylam Official Says Firm Confident in RNAi, Has Cash to Move Drug Candidates into 'Advanced Development'

The statements come just weeks after one-time partner Novartis opted not to take a broad license to Alnylam's technology and Roche halted its in-house RNAi drug efforts.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.